Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.

Dejgaard TF, Schmidt S, Frandsen CS, Vistisen D, Madsbad S, Andersen HU, Nørgaard K

Diabetes, obesity & metabolism19 Dec 2019Cited by 58 (Europe PMC)

PMID31696598DOI10.1111/dom.13911PepBankPUB-31696598

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults with type 1 diabetes on insulin pump therapy, liraglutide reduced HbA1c compared with placebo.
In plain wordsIn overweight adults with type 1 diabetes using an insulin pump, liraglutide lowered HbA1c compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 44
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Measurements
Between-group difference in HbA1c
7 mmol/mol
liraglutide vs placebo
Source sentences
Summary
HbA1c was reduced by 5 mmol/mol (0.5%) from a baseline of 66 mmol/mol (8.2%) in patients treated with liraglutide compared with a non-significant change of +2.3 mmol/mol (0.2%) from a baseline of 66 mmol/mol (8.1%) in patients treated with placebo (between-group difference 7 mmol/mol [0.7%], P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, randomized, double-blind, placebo-controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment.
Report a problemFND-3169659801
02HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults with type 1 diabetes on insulin pump therapy, liraglutide reduced total insulin dose.
In plain wordsIn overweight adults with type 1 diabetes using an insulin pump, liraglutide lowered the total insulin dose needed.
Peptide
Liraglutide
Outcome
DecreaseTotal daily insulin dose
Study
n = 44
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide reduced total insulin dose by 8 units/day or 16% of total insulin dose (P = 0.008).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, randomized, double-blind, placebo-controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment.
Report a problemFND-3169659802
03HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults with type 1 diabetes on insulin pump therapy, liraglutide reduced mean body weight compared with placebo.
In plain wordsIn overweight adults with type 1 diabetes using an insulin pump, liraglutide lowered body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 44
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Measurements
Mean body weight reduction
6.3 kg
liraglutide vs placebo
Source sentences
Summary
Mean body weight was reduced by 6.3 kg (P < 0.001) compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, randomized, double-blind, placebo-controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment.
Report a problemFND-3169659803
04HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults with type 1 diabetes on insulin pump therapy, time spent in the glycaemic target range increased with liraglutide.
In plain wordsIn overweight adults with type 1 diabetes using an insulin pump, liraglutide increased the time that blood sugar stayed in the target range.
Peptide
Liraglutide
Outcome
IncreaseTime in glycaemic target range 4-10 mmol/L
Study
n = 44
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Concomitantly, time spent in glycaemic target range 4-10 mmol/L (71-180 mg/dL) increased while the risk of hypoglycaemia did not differ between groups at the end of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, randomized, double-blind, placebo-controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment.
Report a problemFND-3169659804
05HumanRandomized controlled trialSafety outcome
In overweight or obese adults with type 1 diabetes on insulin pump therapy, the risk of hypoglycaemia did not differ between liraglutide and placebo.
In plain wordsIn overweight adults with type 1 diabetes using an insulin pump, liraglutide did not change the risk of low blood sugar compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeRisk of hypoglycaemia
Study
n = 44
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Concomitantly, time spent in glycaemic target range 4-10 mmol/L (71-180 mg/dL) increased while the risk of hypoglycaemia did not differ between groups at the end of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, randomized, double-blind, placebo-controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment.
Report a problemFND-3169659805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

CompletedPhase 2/3NCT02351232

The Lira Pump Trial

Hvidovre University Hospitaln = 44Feb 2015 to Oct 2016

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 12 Feb 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.